Search | Clinical Trials Finder

Conditions: Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Thromboembolism, Venous Thrombosis
Interventions: edoxaban tosylate(DU-176b), low molecular weight heparin/unfractionated heparin, warfarin; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 8,292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 82
States / cities: Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 71 more

Conditions: Posttraumatic Stress Disorder
Interventions: Prolonged exposure (PE), PE plus Sertraline; Behavioral · Other
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 2
States / cities: Cleveland, Ohio • Seattle, Washington

Conditions: Preeclampsia (PE)
Interventions: Not listed
Lead sponsor: Sequenom, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 6,550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 21
States / cities: Glendale, Arizona • Newark, Delaware • Miami, Florida + 15 more

Conditions: Deep Vein Thrombosis, Fibrillation, Atrial, Venous Thromboembolism, Pulmonary Embolism
Interventions: Odiparcil, Warfarin, Coumadin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 35 Years and older
Enrollment: 961 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 46
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 37 more

Conditions: Pulmonary Embolism, Pulmonary Thromboembolism
Interventions: FlowTriever System, Standard of Care; Device · Procedure
Lead sponsor: Inari Medical; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 15
States / cities: New Haven, Connecticut • Orlando, Florida • Sarasota, Florida + 10 more

Conditions: Teacher Self-efficacy for Teaching PE, Teacher PE Instruction, Student PE Enjoyment, Student Physical Activity, Student PE Satisfaction
Interventions: Digital PE teaching app; Behavioral
Lead sponsor: Saavsus, Inc.; Other
Eligibility: 7 Years and older
Enrollment: 1,872 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Eugene, Oregon • Springfield, Oregon

Conditions: HIV Infections, HIV Seronegativity
Interventions: MTP-PE/MF59, Env 2-3; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1992
U.S. locations: 3
States / cities: Rochester, New York • Nashville, Tennessee • Seattle, Washington

Conditions: Pulmonary Complication, Dyspnea, Pneumonia, COPD, CHF, Atelectasis, PE
Interventions: Incentive Spirometry; Behavioral
Lead sponsor: Jewish Hospital, Cincinnati, Ohio; Other
Eligibility: 65 Years to 99 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Psychogenic Nonepileptic Seizures (PNESs), Post Traumatic Stress Disorder PTSD
Interventions: imaginal and in vivo exposure, psychoeducation for psychogenic nonepileptic seizures; Behavioral
Lead sponsor: Northeast Regional Epilepsy Group; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer
Interventions: Aspiration Thrombectomy; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pulmonary Embolism, Pulmonary Hypertension, Thromboembolism, Right Ventricular Dysfunction
Interventions: Alteplase, EKOS; Drug · Device
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 89 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: Bay Shore, New York • Queens, New York

Conditions: Pulmonary Embolism
Interventions: Echocardiogram; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Stress Disorders, Post-Traumatic, Anxiety Disorders, Mental Disorder, Traumatic Stress Disorder
Interventions: PE+ER; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Pulmonary Embolism, Right Ventricular Dysfunction, Right Ventricular Failure
Interventions: Ultrasound-facilitated, catheter-directed lower-dose fibrinolysis, Tissue Plasminogen Activator; Device · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Premature Ejaculation
Interventions: IX-01, Placebo; Drug
Lead sponsor: Ixchelsis Limited; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 8
States / cities: San Diego, California • Aventura, Florida • West Palm Beach, Florida + 5 more

Conditions: Pulmonary Embolism
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin overlapping with and followed by VKA; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 4,833 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 23
States / cities: Little Rock, Arkansas • Redlands, California • Bay Pines, Florida + 18 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium/Salmeterol QD, Placebo, Salmeterol, Tiotropium/Salmeterol QD+ Salmeterol, Tiotropium (Spiriva®); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 20
States / cities: Boulder, Colorado • Wheat Ridge, Colorado • Winter Park, Florida + 16 more

Conditions: Preterm Birth Complication, Preterm Birth, Preterm Birth Recurrence, Preeclampsia, Preeclampsia (PE), Hypertensive Disorders of Pregnancy, Support Program, Stress, Resilience, Psychological, Empowerment, Patient, Emotional Stress, Pregnancy, Pregnancy Complications, Pregnancy Induced Hypertension, Neonates and Preterm Infants, Cervical Insufficiency, Social Determinants of Health (SDOH), Cervical Shortening, Disparities in Pregnancy Complications, Disparities, Prenatal Care, Care Coordination
Interventions: Care coordination, Electronic massage, support gift #1, Support gift #2, Support gift #3, Support gift #4, Additional PTBCARE+ support, Stress reduction toolkit - Visit 1 (V1), PTBCARE+ mobile application (app) and website, Sleep, meditation, and Wellness app, Emergency low blood sugar kit, Low dose aspirin (LDA), Visit #2 Stress Reduction Toolkit; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Venous Thromboembolism
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin, Placebo: tablet of Rivaroxaban, Placebo: syringes of Enoxaparin; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 3,148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 40
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 36 more

Conditions: Physical Inactivity, Cardiovascular Diseases
Interventions: PE Audit and Feedback Tool; Behavioral
Lead sponsor: University of California, Berkeley; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Fibromyalgia (FM), Posttraumatic Stress Disorder (PTSD)
Interventions: taVNS plus PEPC, sham; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism
Interventions: Angel® Catheter; Device
Lead sponsor: BiO2 Medical; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Jackson, Mississippi • Portland, Oregon • Dallas, Texas + 1 more

Conditions: Post Traumatic Stress Disorder
Interventions: Quetiapine Fumarate, Standard of care meducations; Drug · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Spine Metastasis
Interventions: Apixaban; Drug
Lead sponsor: James Bayley; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Pittburgh, Pennsylvania • Pittsburgh, Pennsylvania

Search by objective public record fields.

Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).

Optimizing Posttraumatic Stress Disorder Treatment: Prolonged Exposure (PE) Versus PE Plus Sertraline

Non-Invasive Preeclampsia Screening and Biobank

Odiparcil For The Prevention Of Venous Thromboembolism

The PERSEVERE Study

Evaluation of Aim to Play, a User-Friendly Digital Application for Teacher Skills Training and Physical Education Activities for 3-5 Grade Students

A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59

Incentive Spirometry in Non-critically Ill Hospitalized Patients With Acute Respiratory Failure

Treatment for Psychogenic Nonepileptic Seizures and Post-traumatic Stress Disorder Using Prolonged Exposure Therapy (PE) or Psychoeducation for PNES

A Prospective Single Center, Single Arm, Single-institution Registry That Aims to Assess the Safety and Quality of Life Benefits of Computer-assisted Vacuum Thrombectomy (CAVT) in the Treatment of Cancer Patients With Intermediate Risk Pulmonary Embolism (PE)

Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE

Inter-Observer Reliability and Accuracy of Tricuspid Annular Plane Systolic Excursion in Patients With Suspected PE in the ED

PTSD Treatment and Emotion Regulation Skills Training for Veterans With Military Sexual Trauma (PE+ER)

Augmented Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for PE

IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE)

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study

Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)

Personalized Care for Prenatal Stress Reduction & Prevention of Preterm Birth (PTB) Disparities

Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.

PE Audit and Feedback Pilot Study

Treatment of Fibromyalgia and PTSD With Live and Inactive Vagus Nerve Stimulation With PEPC

Angel® Catheter Early Feasibility Clinical Study

Quetiapine Augmentation of PE Therapy for the Treatment of Co-occurring PTSD and Mild Traumatic Brain Injury

Extended Prophylactic Anticoagulation Following Spinal Surgery for Metastatic Disease